AZD2693
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Steatohepatitis (NASH)
Conditions
Non-alcoholic Steatohepatitis (NASH)
Trial Timeline
Nov 6, 2020 → Dec 18, 2023
NCT ID
NCT04483947About AZD2693
AZD2693 is a phase 1 stage product being developed by AstraZeneca for Non-alcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT04483947. Target conditions include Non-alcoholic Steatohepatitis (NASH).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05919069 | Phase 1 | Completed |
| NCT05809934 | Phase 2 | Completed |
| NCT04483947 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Steatohepatitis (NASH)